KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) EPS (Basic) (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of EPS (Basic) data on record, last reported at $1.57 in Q2 2025.

  • For Q2 2025, EPS (Basic) rose 2146.84% year-over-year to $1.57; the TTM value through Jun 2025 reached $1.57, up 331.29%, while the annual FY2024 figure was $2.47, 142.59% up from the prior year.
  • EPS (Basic) reached $1.57 in Q2 2025 per SRPT's latest filing, down from $1.67 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $1.67 in Q4 2024 and bottomed at -$2.94 in Q3 2022.
  • Average EPS (Basic) over 5 years is -$0.63, with a median of -$0.6 recorded in 2021.
  • Peak YoY movement for EPS (Basic): plummeted 813.04% in 2021, then soared 2146.84% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at -$1.43 in 2021, then increased by 13.29% to -$1.24 in 2022, then soared by 161.29% to $0.76 in 2023, then soared by 119.74% to $1.67 in 2024, then dropped by 5.82% to $1.57 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were $1.57 in Q2 2025, $1.67 in Q4 2024, and $0.36 in Q3 2024.